S. Hautaniemi

This study reprograms human fibroblasts to pancreatic exocrine cells using six transcription factors and identifies transient progenitor states as key intermediates in the process.

This study identifies CK2 inhibition as a sensitizing strategy for RB1-deficient ovarian and breast cancer cells to replication-perturbing drugs, showing enhanced efficacy when combined with existing therapies.

The paper identifies common downstream mechanisms driven by lineage-specific oncogenes that regulate cell proliferation in various cancers.

The paper investigates L1 retrotransposition in HGSC, finding that despite high L1 mRNA expression, only a third of tumors show somatic insertions, with variability in retrotransposition frequency and patterns.

This study identifies three evolutionary states of ovarian high-grade serous carcinoma using whole-genome sequencing and links them to distinct therapeutic targets.

This paper describes a method to generate and expand high-grade serous ovarian cancer organoids with improved success rates and reports their drug response correlation with clinical outcomes.

The paper develops a tumor-specific method to detect allelic imbalances for HRD prediction, showing improved clinical outcome prediction in ovarian and breast cancers.

This study identifies epigenetic inhibitors that enhance the effectiveness of immunochemotherapy in DLBCL by disrupting DNA repair and cell cycle pathways.